SURPASS-2
In SURPASS-2, a 40-week trial in Mounjaro's FDA label, 1,879 adults with type 2 diabetes already taking metformin were given Mounjaro 5, 10 or 15 mg, or semaglutide 1 mg (the medicine in Ozempic), once a week.
HbA1c, a measure of average blood sugar, fell by 2.0, 2.2 and 2.3 points on Mounjaro 5, 10 and 15 mg, and by 1.9 on semaglutide 1 mg. The label says the 10 mg and 15 mg results were statistically significantly better than semaglutide's.
Weight fell by 7.6, 9.3 and 11.2 kg on Mounjaro 5, 10 and 15 mg, and by 5.7 kg on semaglutide 1 mg.
The trial used semaglutide 1 mg. Ozempic's label now also allows 2 mg, which this trial didn't test.